Watch the latest FAIRplus webinar
FAIR data and COVID-19
Guy Cochrane (EMBL-EBI) helps us understand the importance of FAIR principles when sharing COVID-19 research data.
Members of the FAIRplus consortium at the FAIRplus General Assembly 30-31 January 2020 in Hinxton, UK.
Introduction to the FAIRplus project
The FAIRplus project aims to develop tools and guidelines for making life science data FAIR (Findable, Accessible, Interoperable, Reusable). The project has 22 partners from academia and industry, and runs from January 2019 to June 2022. See
About the project and the news story on the ELIXIR website.
ELIXIR and Janssen Goals
To establish a process for selecting and prioritising IMI project databases for FAIRification.
To develop guidelines, tools and metrics needed to make data Findable, Accessible, Interoperable and Reusable (FAIR).
To deliver tailored training for data handlers (academia, SMEs and pharmaceuticals).
To change and sustain the data management culture in pharma, academia and SMEs.
To organise FAIR 'Innovation and SME Events' to foster an innovation ecosystem on FAIR open data to power future reuse, knowledge generation, and societal benefit.
22 participants (12 academic, 7 EFPIA, 3 SME)
Work Packages and their leaders
Philip Gribbon (Fraunhofer)
Ola Engkvist (AstraZeneca) David Henderson (Bayer)
Susanna-Assunta Sansone (University of Oxford, ELIXIR UK)
Andrea Splendiani (Novartis)
Helen Parkinson (EMBL-EBI, ELIXIR)
Rudi Verbeeck (Janssen)
Jan-Willem Boiten (Lygature)
George Papadatos (GSK) Colin Wood (AstraZeneca)
Serena Scollen (ELIXIR Hub)
Herman Van Vlijmen (Janssen)
Anne Cambon-Thomsen (Université Paul Sabatier Toulouse III)
Herman Van Vlijmen (Janssen) Duration
42 months (January 2019 - June 2022)
€8.23M (€4M H2020 EC funding, €4.23M EFPIA in-kind)
See also the
factsheet on the IMI website.